Page last updated: 2024-11-07
spironolactone and ADPKD
spironolactone has been researched along with ADPKD in 1 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "61 adults aged 20 to 55 years with ADPKD, estimated glomerular filtration rate ≥ 60mL/min/1." | 2.90 | Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial. ( Chonchol, M; Farmer-Bailey, H; George, D; Gitomer, B; Jovanovich, A; Klawitter, J; Malaczewski, M; Nowak, KL; Patel, N; Wang, W; You, Z, 2019) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Nowak, KL | 1 |
| Gitomer, B | 1 |
| Farmer-Bailey, H | 1 |
| Wang, W | 1 |
| Malaczewski, M | 1 |
| Klawitter, J | 1 |
| You, Z | 1 |
| George, D | 1 |
| Patel, N | 1 |
| Jovanovich, A | 1 |
| Chonchol, M | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney[NCT01853553] | Phase 3 | 61 participants (Actual) | Interventional | 2013-07-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change From Baseline in Flow Mediated Dilation at 6 Months.
FMD will be determined using high-resolution ultrasonography (NCT01853553)
Timeframe: Baseline and 6 months.
| Intervention | Percent change. (Mean) |
|---|
| Spironolactone | -0.2 |
| Sugar Pill | -0.4 |
Change From Baseline in Vascular Stiffness at 6 Months.
Aortic pulse wave velocity, a measure of large elastic arterial stiffness, and carotid compliance, a measure of large artery distensibility, will be determined. A transcutaneous custom tonometers (Noninvasive Hemodynamics Workstation, Cardiovascular Engineering Inc., Norwood, MA) will be positioned at the aorta and femoral artery to measure pulse wave velocity, and carotid artery compliance (and the β-stiffness index, a more blood pressure independent measure of local arterial stiffness) will be measured non-invasively using simultaneous high-resolution ultrasonography and applanation tonometry). Higher values correspond to greater stiffness. (NCT01853553)
Timeframe: Baseline and 6 months
| Intervention | m/s (Median) |
|---|
| Spironolactone | -37 |
| Sugar Pill | -1 |
Trials
1 trial available for spironolactone and ADPKD